Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6%

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 3,150,000 shares, an increase of 8.6% from the November 15th total of 2,900,000 shares. Approximately 6.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 321,400 shares, the short-interest ratio is currently 9.8 days.

Astria Therapeutics Stock Performance

NASDAQ ATXS traded down $0.29 on Friday, reaching $9.52. The company's stock had a trading volume of 195,675 shares, compared to its average volume of 593,820. Astria Therapeutics has a twelve month low of $5.80 and a twelve month high of $16.90. The firm's 50 day moving average is $10.82 and its two-hundred day moving average is $10.70. The stock has a market cap of $537.21 million, a PE ratio of -4.56 and a beta of 0.67.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $25.60.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATXS. Charles Schwab Investment Management Inc. raised its stake in Astria Therapeutics by 152.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company's stock valued at $3,460,000 after purchasing an additional 189,727 shares during the period. FMR LLC raised its position in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock valued at $86,123,000 after buying an additional 1,767,714 shares during the period. Vestal Point Capital LP raised its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company's stock valued at $44,040,000 after buying an additional 750,000 shares during the period. Sofinnova Investments Inc. purchased a new stake in Astria Therapeutics in the 2nd quarter worth about $552,000. Finally, ClariVest Asset Management LLC acquired a new stake in Astria Therapeutics during the 2nd quarter worth about $731,000. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.